Intelligent Bio Solutions reported a record fiscal Q1 2027 revenue of $1.39 million, a 25% increase year-over-year, driven mainly by higher-margin cartridge sales which grew 32%. The company also expanded its gross profit margin to 54.5%, up from 46.6% last year, reflecting manufacturing efficiencies. A key milestone was submitting the FDA 510(k) premarket notification for its Intelligent Fingerprinting Drug Screening System, aiming for U.S. market entry. With growing customer accounts and installed base, the company is positioned for continued growth in the multi-billion-dollar U.S. drug screening market.
Intelligent Bio Solutions reported record fiscal Q1 2027 revenue of $1.39 million. For readers following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 19:42 WIB: 83 of 150 priced US health stocks rose today. Notable movers include DNA at USD 12.17 with a 1-day change of -1.62%, RVTY at USD 163.18 with +1.53%, and RXRX at USD 3.75 with -1.45%.
project44 has partnered with Snowflake to enhance supply chain decision-making through Mo, an AI-powered supply chain analyst. Mo uses project44's extensive logistics data and Snowflake Cortex AI to provide accurate, consistent answers to complex sup...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
